Today: 30 June 2026
Browse Category

NASA 8 June 2025 - 21 June 2025

Unlocking the Sun: Inside NASA and ESA’s Daring Missions to Touch the Solar Inferno

Unlocking the Sun: Inside NASA and ESA’s Daring Missions to Touch the Solar Inferno

The Sun is our life-giving star – a 4.6-billion-year-old solar inferno that governs Earth’s climate and space environment. Understanding the Sun is not only vital for fundamental science, but also for protecting modern technology and astronauts from space weather nasa.gov nasa.gov. Yet many solar mysteries endure, such as why the Sun’s outer atmosphere blazes hundreds of times hotter than its surface, or how the solar wind – a stream of charged particles flowing outward – is accelerated to high speeds. In the past, scientists could only observe the Sun from afar. Now, two bold spacecraft are “touching” the Sun up close: NASA’s Parker Solar Probe and the ESA/NASA Solar Orbiter. These missions are venturing closer to our star than ever before, braving intense heat and radiation to unlock the Sun’s deepest secrets science.nasa.gov esa.int. This report delves into these daring missions – their objectives, designs, key discoveries, and how together they are revolutionizing solar physics. Launched by NASA in August 2018, the Parker Solar Probe is humanity’s first mission to fly through the Sun’s corona – literally touching the Sun nasa.gov. It is named after solar physicist Eugene Parker, who first predicted the solar wind in 1958 cosmos.esa.int. Parker Solar

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Go toTop